[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569193":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":19,"locations":25,"responsibleParty":37,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Humanitas Clinical and Research Center","OTHER",null,[9,13,16],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Vedolizumab","UC patients treated with vedolizumab",{"type":10,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"Ustekinumab - Standard Dosage","UC patients treated with ustekinumab",{"type":10,"name":17,"description":18,"armGroupLabels":7,"otherNames":7},"JAK Inhibitor","UC patients treated with JAK inhibitors",[20],{"name":21,"role":22,"phone":23,"phoneExt":7,"email":24},"Alessandro Armuzzi","CONTACT","+39 02 8224 5555","alessandro.armuzzi@hunimed.eu",[26],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":30,"countryCode":32,"cosmosGeoPoint":7,"geoPoint":7,"contacts":33},"Humanitas Research Hospital IRCSS","RECRUITING","Mialn","Italy","00168","IT",[34],{"name":21,"role":22,"phone":35,"phoneExt":7,"email":36},"0630159357","alearmuzzi@yahoo.com",{"type":38,"investigatorFullName":21,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Professor","100569193","the-podium-study---a-three-arm-comparison-of-target-therapies-after-anti-tnf-in-ulcerative-colitis-100569193",false,"NCT06691061","The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis","Real-life Comparative Effectiveness of Vedolizumab, Ustekinumab and JAK Inhibitors in Patients with Ulcerative Colitis After Anti-TNFα Failure or Intolerance","Inclusion Criteria:\n\n* Established diagnosis of UC according to the current European Crohn's and Colitis Organization (ECCO) guidelines7;\n* Age ≥ 18 years-old;\n* Capability of expressing informed consent;\n* Clinically active ulcerative colitis (cf. 'operative clinical measures', below) at baseline;\n* Initiation of vedolizumab, ustekinumab or JAK inhibitors (tofacitinib, upadacitinib or filgotinib) as second-line target therapy at baseline;\n* Previous treatment with at least one anti-TNFα drug licenced for the treatment of UC (i.e., infliximab, adalimumab and\u002For golimumab);\n* No exposure to vedolizumab, ustekinumab and JAK inhibitors before baseline;\n* At least 1 follow-up visit after baseline\n\nExclusion Criteria:\n\n* Diagnosis of Crohn's colitis, IBD-U or other gastrointestinal inflammatory conditions;\n* Age \\\u003C 18 years-old;\n* Incapability of expressing informed consent;\n* Acute severe UC requiring hospitalization at baseline;\n* No previous exposure to anti-TNFα therapies;\n* Previous treatment with target therapies other than anti-TNF-α for UC before baseline;\n* Ustekinumab or JAK inhibitors induction with a non-standard posology for UC.","ALL","18 Years",{"count":50,"type":51},450,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to compare the real-life effectiveness and safety of vedolizumab, ustekinumab and JAK inhibitors in patients with UC who had been exposed to at least one anti-TNF-alpha therapy.",[55],"Ulcerative Colitis (Disorder)","2024-11-14",{"date":58,"type":59},"2024-11-15","ACTUAL",{"date":61,"type":59},"2023-08-01",{"date":63,"type":51},"2024-12-31",{"name":5,"class":6},1]